Altimmune (ALT) Other Accumulated Expenses (2014 - 2026)
Altimmune (ALT) posted quarterly Other Accumulated Expenses of $313000.0 for Q1 2026, up 458.93% year-over-year from $56000.0 in Q1 2025, and down 0.63% quarter-over-quarter from $315000.0 in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Other Accumulated Expenses (2014 - 2026) Analysis & Trends
Altimmune (ALT) has reported Other Accumulated Expenses for 9 consecutive years, with $313000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 458.93% year-over-year to $313000.0; the TTM figure through Mar 2026 stood at $313000.0 (up 458.93% YoY), while the FY2025 annual figure was $315000.0, up 472.73% from the prior year.
- Other Accumulated Expenses declined to $313000.0 in Q1 2026 per ALT's latest filing, from $315000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $315000.0 in Q4 2025 and bottomed at $54000.0 in Q3 2024.
- Historically, Other Accumulated Expenses has averaged $137727.3 across 5 years, with a median of $103000.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses sank 55.65% — and 2025, when it surged 472.73%.
- Altimmune's Other Accumulated Expenses stood at $103000.0 in 2022, then advanced by 20.39% to $124000.0 in 2023, then tumbled by 55.65% to $55000.0 in 2024, then soared by 472.73% to $315000.0 in 2025, then decreased by 0.63% to $313000.0 in 2026.
- Business Quant data shows ALT's Other Accumulated Expenses at $313000.0 in Q1 2026, $315000.0 in Q4 2025, and $177000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 313,000.00 |
| Mar 31, 2026 | 313,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 183,000.00 |
| Mar 31, 2025 | 56,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 124,000.00 |
| Dec 31, 2022 | 103,000.00 |
| Mar 31, 2017 | 11,588.00 |
| Dec 31, 2016 | 11,588.00 |
| Sep 30, 2016 | 11,588.00 |
| Jun 30, 2016 | 11,588.00 |
| Dec 31, 2015 | 11,250.00 |
| Jun 30, 2015 | 74,233.00 |
| Mar 31, 2015 | 72,674.00 |
| Dec 31, 2014 | 70,326.00 |